BACKGROUND AND OBJECTIVES: Neovascular @entity1020 ( @entity1020 ) is a chronic and @entity179 . Current treatment options are limited and have shown to slow disease progression. The aim of this study was to assess Ranibizumab effectiveness and safety and to describe @entity1 ' demographic and clinical characteristics. @entity1 AND METHOD: We conducted a retrospective observational study including all @entity1 who had started treatment between 1/12/2006 and 31/12/2008, and were followed up until 31/03/2009. A bivariate analysis on months 4, 12 and 18 and two logistic regression models were performed to analyze the influence of demographic and clinical factors on the effectiveness and durability of treatment. Adverse reactions were collected as described in the medical records to assess safety. RESULTS: A total of 126 eyes of 112 @entity1 were recruited. The mean age was 77.7 (   6.0) years. The mean durability of treatment was 18.2 months, and it was higher in the group of @entity1 who started treatment with visual acuity (VA) > 0.1 (p<0.001). Ranibizumab therapy maintained AV over baseline at 18 months. None of the studied variables showed any influence on treatment effectiveness. However, baseline visual acuity influenced on treatment duration, being higher in the group of @entity1 with AV > 0.1. CONCLUSIONS: Ranibizumab was shown to be effective until 18 months. Early diagnosis of @entity13785 could lead to an earlier treatment start, when @entity1 present a higher AV, in order to optimize the benefits of treatment. Ranibizumab was well tolerated and safe in most @entity1 .

[Assessment of the effectiveness and safety of ranibizumab in neovascular age-related XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['Age Related Macular Degeneration', 'ARMD'] @entity179 :: ('MESH:D019636', 'Disease') :: ['degenerative disease'] @entity13785 :: ('MESH:D006009', 'Disease') :: ['AMD']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
